Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1969 1
1970 1
1974 1
1978 1
1984 2
1987 1
1989 2
1991 1
1995 1
1998 3
1999 1
2001 1
2002 1
2003 3
2004 2
2005 1
2006 3
2007 3
2008 6
2009 2
2010 5
2011 5
2012 6
2013 14
2014 6
2015 4
2016 2
2018 7
2019 10
2020 11
2021 13
2022 12
2023 19
2024 12
2025 9

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

155 results

Results by year

Filters applied: . Clear all
Page 1
Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS.
Miller TM, Cudkowicz ME, Genge A, Shaw PJ, Sobue G, Bucelli RC, Chiò A, Van Damme P, Ludolph AC, Glass JD, Andrews JA, Babu S, Benatar M, McDermott CJ, Cochrane T, Chary S, Chew S, Zhu H, Wu F, Nestorov I, Graham D, Sun P, McNeill M, Fanning L, Ferguson TA, Fradette S; VALOR and OLE Working Group. Miller TM, et al. N Engl J Med. 2022 Sep 22;387(12):1099-1110. doi: 10.1056/NEJMoa2204705. N Engl J Med. 2022. PMID: 36129998 Free article. Clinical Trial.
Efficacy and safety of vutrisiran for patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy: a randomized clinical trial.
Adams D, Tournev IL, Taylor MS, Coelho T, Planté-Bordeneuve V, Berk JL, González-Duarte A, Gillmore JD, Low SC, Sekijima Y, Obici L, Chen C, Badri P, Arum SM, Vest J, Polydefkis M; HELIOS-A Collaborators. Adams D, et al. Amyloid. 2023 Mar;30(1):1-9. doi: 10.1080/13506129.2022.2091985. Epub 2022 Jul 23. Amyloid. 2023. PMID: 35875890 Free article. Clinical Trial.
Efficacy, safety and tolerability of rozanolixizumab in patients with chronic inflammatory demyelinating polyradiculoneuropathy: a randomised, subject-blind, investigator-blind, placebo-controlled, phase 2a trial and open-label extension study.
Querol L, De Sèze J, Dysgaard T, Levine T, Rao TH, Rivner M, Hartung HP, Kiessling P, Shimizu S, Marmol D, Bozorg A, Colson AO, Massow U, Eftimov F; CIDP01 Study Investigators. Querol L, et al. J Neurol Neurosurg Psychiatry. 2024 Aug 16;95(9):845-854. doi: 10.1136/jnnp-2023-333112. J Neurol Neurosurg Psychiatry. 2024. PMID: 38729747 Free PMC article. Clinical Trial.
[Blast lung injuries].
Clapson P, Pasquier P, Perez JP, Debien B. Clapson P, et al. Rev Pneumol Clin. 2010 Sep;66(4):245-53. doi: 10.1016/j.pneumo.2010.07.008. Epub 2010 Sep 21. Rev Pneumol Clin. 2010. PMID: 20933166 Review. French.
[Surgical deductions].
Ecuyer J, Debien J. Ecuyer J, et al. Actual Odontostomatol (Paris). 1984 Dec;38(148):695-702. Actual Odontostomatol (Paris). 1984. PMID: 6599376 French. No abstract available.
Kell Blood Group System.
Maheshwari A, Zubair M, Maheshwari A. Maheshwari A, et al. 2024 Oct 28. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–. 2024 Oct 28. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–. PMID: 39536149 Free Books & Documents.
Depressed Kell antigen (Cellano) in Gerbich-negative phenotypes: Both Muller and Debien reported reduced expression of 'k' antigens in RBCs of Gerbich group-negative phenotype (Ge:-2,-3) in individuals using monoclonal anti-k. ...
Depressed Kell antigen (Cellano) in Gerbich-negative phenotypes: Both Muller and Debien reported reduced expression of 'k' antigens i …
[Suicide in prison: Epidemiology and prevention].
Eck M, Scouflaire T, Debien C, Amad A, Sannier O, Chan Chee C, Thomas P, Vaiva G, Fovet T. Eck M, et al. Presse Med. 2019 Jan;48(1 Pt 1):46-54. doi: 10.1016/j.lpm.2018.11.009. Epub 2019 Jan 23. Presse Med. 2019. PMID: 30685227 Review. French.
Safety and efficacy of arimoclomol in patients with early amyotrophic lateral sclerosis (ORARIALS-01): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial.
Benatar M, Hansen T, Rom D, Geist MA, Blaettler T, Camu W, Kuzma-Kozakiewicz M, van den Berg LH, Morales RJ, Chio A, Andersen PM, Pradat PF, Lange D, Van Damme P, Mora G, Grudniak M, Elliott M, Petri S, Olney N, Ladha S, Goyal NA, Meyer T, Hanna MG, Quinn C, Genge A, Zinman L, Jabari D, Shoesmith C, Ludolph AC, Neuwirth C, Nations S, Shefner JM, Turner MR, Wuu J, Bennett R, Dang H, Sundgreen C; ORARIALS-01 trial team. Benatar M, et al. Lancet Neurol. 2024 Jul;23(7):687-699. doi: 10.1016/S1474-4422(24)00134-0. Epub 2024 May 20. Lancet Neurol. 2024. PMID: 38782015 Clinical Trial.
155 results